Ertapenem
Based on 12 publication(s) in Google Scholar
Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract.
For research use only. We do not sell to patients.
- CAS No.: 153832-46-3
- Formula: C22H25N3O7S
- Molecular Weight:475.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ertapenem
More- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Nat Commun. 2021 Jul 22;12(1):4461. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Dec 2;122(48):e2524436122. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2314514121. [Abstract]
- J Clin Microbiol. 2024 May 7:e0152023. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Antimicrob Chemother. 2023 Sep 5;78(9):2242-2253. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- Adv Ther (Weinh). 2024 Jan 12.
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
All Antibiotic Isoforms
More
Biological Activity
|
β-lactam |
Ertapenem (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B. fragilis (ATCC 25285), B. thetaiotaomicron (ATCC 29741), and Eubacterium lentum (ATCC 43055)
-
Concentration:0-100 μg/mL approximately
-
Incubation Time:48 h
-
Result:Inhibited 99.1% of all isolate with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and 98.8% of the isolates were susceptible among the B. fragilis group.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:S. aureus thigh tissue infection model (DBA/2 mice)[2]
-
Dosage:0.5,1, 2, 5, 10 mg/kg (given at 2, 6, 10, 24, 48, 72, 96, 120 h)
-
Administration:Subcutaneous injection (0.5 mL after infection)
-
Result:Displayed > 3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg. Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg.
-
Animal Model:Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)[2]
-
Dosage:0-3 mg/kg approximately
-
Administration:Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection)
-
Result:Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of <0.25 mg/kg/dose.
-
Animal Model:CD-1 mice, rats[2]
-
Dosage:10 mg/kg approximately
-
Administration:Intraperitoneal injection (pharmacokinetic assay)
-
Result:Exhibited an AUC0-∞ ranging from 1.8-21.82 μg•hr/mL in tissue in mice following a 10-mg/kg i.p. dose. Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15μg•hr/mL.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 153832-46-3
-
Molecular Weight 475.51
-
Formula C22H25N3O7S
-
SMILES
O=C(C(N12)=C(S[C@@H]3CN[C@H](C(NC4=CC=CC(C(O)=O)=C4)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O
-
Synonyms
MK-0826
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
Nat Commun
An on-demand, drop-on-drop method for studying enzyme catalysis by serial crystallography. [Abstract]2021 Jul 22;12(1):4461. PMID: 34294694 -
Proc Natl Acad Sci U S A
Antibiotics accumulate in Klebsiella pneumoniae liver abscesses but fail to eliminate antibiotic-tolerant populations. [Abstract]2025 Dec 2;122(48):e2524436122. PMID: 41296732 -
Proc Natl Acad Sci U S A
In-patient evolution of a high-persister Escherichia coli strain with reduced in vivo antibiotic susceptibility. [Abstract]2024 Jan 16;121(3):e2314514121. PMID: 38190524 -
J Clin Microbiol
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. [Abstract]2024 May 7:e0152023. PMID: 38712928 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Antimicrob Chemother
Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians. [Abstract]2023 Sep 5;78(9):2242-2253. PMID: 37522258 -
J Antimicrob Chemother
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]2020 Jul 1;75(7):1850-1858. PMID: 32154866 -
-
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936
Purity & Documentation
References
[1]. Kenneth E Aldridge. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis. 2002 Oct;44(2):181-6. [Content Brief]
[2]. C J Gill, et al. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother. 1998 Aug;42(8):1996-2001. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz